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Abstract 
Introduction: Previous research suggests there may be differences in the effects of adrenaline 
related to the initial cardiac arrest rhythm.  The aim of this study was to assess the effect of 
adrenaline compared with placebo according to whether the initial cardiac arrest rhythm was 
shockable or non-shockable. 
 
Methods: Return of spontaneous circulation (ROSC), survival and neurological outcomes 
according to the initial arrest rhythm were compared amongst patients enrolled in the 
PARAMEDIC-2 randomised, placebo controlled trial.  The results of the PARAMEDIC-2 and 
PACA out of hospital cardiac arrest trials were combined and meta-analysed. 
 
Results: The initial rhythm was known for 3,929 (98.2%) in the placebo arm and 3,919 (97.6%) 
in the adrenaline arm.  The effect on the rate of ROSC of adrenaline relative to placebo was 
greater in patients with non-shockable cardiac rhythms (1002/3003 (33.4%) versus 222/3005 
(7.4%), adjusted OR: 6.5, (95% CI 5.6-7.6)) compared with shockable rhythms 349/716 (48.7%) 
versus (208/702 (29.6%), adjusted OR: 2.3, 95%CI: 1.9-2.9)).  The adjusted odds ratio for 
survival at discharge for non-shockable rhythms was 2.5 (1.3, 4.8) and 1.3 (0.9, 1.8) for 
shockable rhythms (P value for interaction 0.065) and 1.8(0.8-4.1) and 1.1 (0.8-1.6) 
respectively for neurological outcome at discharge (P value for interaction 0.295). Meta-
analysis found similar results.    
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Conclusion: Relative to placebo, the effects of adrenaline ROSC are greater for patients with 
an initially non-shockable rhythm than those with a shockable rhythms.  Similar patterns are 
observed for longer term survival outcomes and favourable neurological outcomes, although 
the differences in effects are less pronounced. ISRCTN73485024   
 
Word count: 250 
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Introduction 
Adrenaline has been used as a treatment for cardiac arrest for many years.1-3  Despite its 
widespread use, until recently there has been limited evidence from randomised, placebo 
controlled trials about its safety and effectiveness.4,5  The Cochrane systematic review and 
meta-analysis identified two randomised controlled trials which enrolled patients before 
admission to hospital and allocated them to adrenaline (1 mg aliquots) or placebo.4  The Pre-
hospital Adrenaline for Cardiac Arrest (PACA) trial6 and Prehospital Assessment of the Role of 
Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest 
(PARAMEDIC-2)7 enrolled 8,534 patients with out of hospital cardiac arrest (OHCA) and 
allocated them to receive adrenaline (1 mg every 3-5 minutes) or placebo.  Meta-analysis of 
the trial results showed that adrenaline increased the rate of return of spontaneous 
circulation (ROSC) and survival to hospital discharge, but did not find evidence of improved 
neurological outcomes.4 
 
Observational studies suggest that there may be differences in the effects of adrenaline 
according to the initial cardiac arrest heart rhythm.  Administration of adrenaline in patients 
with initially shockable rhythms may be less effective8 or potentially harmful.9,10  Although 
overall outcomes are generally poorer in patients with non-shockable rhythms, the 
incremental effectiveness of adrenaline by contrast appears to be greater.8-11  Although 
informative, observational studies are limited by the risk of bias due to un-measured 
confounding factors.  This includes the potential association between adrenaline being given 
later in patients with initially shockable rhythms, which might introduce resuscitation time 
bias.12  
  
The aim of this study was (i) to assess the effect of initial arrest rhythm (i.e. shockable vs non-
shockable) on primary and secondary outcomes in the PARAMEDIC-2 trial7 (ii) to provide a 
meta-analysis to assess the effect of initial rhythm on a set of outcomes that were common 
to the PARAMEDIC-2 and PACA trial.6  
 
Methods 
 
Study design and patients 
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PARAMEDIC-2 trial (2018) 
The background to the trial, methods and baseline characteristics of the randomised patients 
have been previously reported.7,13 In brief, PARAMEDIC-2 was a multicentre double-blinded 
placebo-controlled trial conducted by five National Health Service ambulance services in the 
United Kingdom from December 2014 to October 2017 inclusive. Patients treated by 
ambulance paramedics for OHCA who were not successfully resuscitated by means of 
defibrillation or cardiopulmonary resuscitation (CPR), and who met predetermined eligibility 
criteria were randomly allocated to either adrenaline or saline placebo. Randomisation 
occurred when trial paramedics opened packs containing ten prefilled syringes loaded with 
either 1 mg doses of adrenaline or 0.9% saline. Treatment was administered by intravenous 
(IV) or intraosseous (IO) route. In accordance with European Resuscitation Council 
Guidelines14 the intervention was administered as soon as possible (after initiating CPR and 
obtaining vascular access) if the initial rhythm was non-shockable.  For initially shockable 
rhythms, the intervention was deferred until either the rhythm changed to non-shockable or 
the third attempt at defibrillation was unsuccessful. Trial packs and their contents were 
identical in appearance and carried a unique identification number. In all other respects 
identical paramedic resuscitation protocols were followed.15,16 
 
Randomisation of drug packs to ambulance services was achieved using computer-generated 
randomisation with an allocation ratio of 1:1. Patients, paramedics and trial staff were blinded 
to treatment allocation. A full description of trial methods has been previously published.13 
 
PACA trial (2011) 
 
The PACA trial was a double-blind randomised placebo controlled trial of the effect of 
adrenaline on survival in 534 OHCA patients conducted in Australia from August 2006 to 
November 2009.6  The eligibility criteria for this trial were similar to that of PARAMEDIC-2: all 
patients with an OHCA from any cause, age 18 or older with resuscitation commenced by 
paramedics were entered into the study.  Local protocols for the timing of drug administration 
were the same as for the PARAMEDIC-2 trial. Clinical outcomes collected were similar to those 
of the PARAMEDIC-2 study. However, in relation to initial rhythm, only the ROSC at any time 
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(reported as ROSC achieved pre-hospital) and survived to hospital discharge were reported.  
Survival with favourable neurological outcome (Cerebral Performance Category 1,2) was 
extracted from the trial database for inclusion in the meta-analysis.   
 
Statistical analysis 
PARAMEDIC-2 study 
For analysis purposes initial arrest rhythm was subdivided into 2 categories: (i) shockable 
(consisting of ventricular fibrillation (VF), pulseless ventricular tachycardia (VT), and 
automated external defibrillator (AED) shockable rhythms), and (ii) non-shockable (consisting 
of asystole, pulseless electrical activity (PEA), bradycardia, and AED non-shockable rhythms). 
Observations with missing rhythm type were removed before analysis. 
All statistical analyses were undertaken using Stata, version 15.1. 
We assessed the primary outcome: rate of survival at 30 days, and secondary outcomes: rate 
of survival at discharge from hospital, rate of survival at 3 months, rate of return of 
spontaneous circulation (ROSC) at hospital admission, ROSC at any time, rate of favourable 
neurological outcome at discharge, and rate of favourable neurological outcome at 3 months, 
by initial arrest rhythm type. The neurological outcomes were determined using a modified 
Rankin scale assessment (ranging from 0 [no symptoms] to 6 [death]) where a score of 0-3 
inclusive was considered favourable.17 
 
Logistic regression models were fitted for each of the seven pre-specified outcomes as 
dependent variables. The unadjusted analyses included dichotomous rhythm type and 
allocated treatment as explanatory factors. An interaction of these latter two variables was 
fitted to assess the heterogeneity of treatment effects. This was assessed using the chi-
squared test. We also fitted adjusted logistic regression models where the models were 
corrected for pre-specified covariates (1) which included age, gender, interval between 
emergency call and ambulance arrival at scene, interval between arrival at scene and 
administration of trial drug, aetiology (medical, traumatic, drowning, drug overdose, 
electrocution, asphyxial), witness type (unwitnessed, Emergency Medical Service (EMS), 
bystander), and bystander CPR (yes, no). Odds ratios and 95% confidence intervals were 
estimated for the different categories of rhythm. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
 
OFFICIAL - Business data that is not intended for public consumption. However, this can be shared with external partners, as required. 
 
Meta-analysis 
A meta-analysis was conducted using the common outcome variables to both studies, namely 
ROSC at any time and survival to hospital discharge.   Results for favourable neurological 
outcome at discharge not reported in the PACA trial have been provided to enable meta-
analysis (note that a Cerebral Performance Category (CPC) score of 1-2 was deemed 
equivalent to an mRS score of 0-3).  Random effects models were fitted to combine the data 
on both these trials (with adjustment for dichotomous rhythm type and treatment allocation 
only). Pooled estimates of effect (odds ratio) and 95% confidence intervals were produced. 
Between-study statistical heterogeneity was assessed using the I-squared method, and the 
Mantel-Haenszel Q test was used to examine heterogeneity between types of rhythm. 
 
Role of the funding source 
The PARAMEDIC 2 trial was funded by the Heath Technology Assessment Programme of the 
National Institute for Health Research. The funders had no role in the trial design, data 
collection or analysis, or in the writing of this report. The Warwick Clinical Trials Unit 
undertook data management activities. The trial statisticians (CK, CJ, RL) assume 
responsibility for the integrity of the data and its analysis. The NIHR Current Controlled Trials 
number is ISRCTN73485024. 
The PACA trial was funded by the NHMRC (Australia) and registered under the Australian and 
New Zealand Clinical Trials Register (ACTRN12605000062628). 
 
 
Results 
PARAMEDIC-2 Study 
Of 8,014 patients enrolled in the study those with known treatment allocation consisted of 
3,999 in the placebo and 4,015 in the adrenaline arm. Removal of cases where initial cardiac 
rhythm was unknown (166 in total), reduced the numbers to 3,929 (98.2%) and 3,919 (97.6%) 
respectively. These cases were analysed with the exception of those lost to follow up. A 
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CONSORT diagram demonstrates the number of patients in each group (after excluding those 
where the initial arrest rhythm was not recorded) and rates of loss to follow-up (Figure 1). 
Baseline characteristics for trial patients according to initial cardiac arrest rhythm are shown 
in Table 1.  
Return of spontaneous circulation (figure 2) 
Of those patients with non-shockable rhythms 1002/3003 (33.37%) achieved ROSC in the 
adrenaline group and 222/3005 (7.39%) achieved ROSC in the placebo group (adjusted OR: 
6.52, 95% CI 5.56-7.63). Of those patients with shockable rhythms 349/716 (48.74%) achieved 
ROSC in the adrenaline group compared to 208/702 (29.63%) in the placebo group (adjusted 
OR: 2.32, 95%CI: 1.86-2.89).  The interaction term of rhythm type and treatment 
demonstrates that the effect of adrenaline on ROSC is greater in patients with non-shockable 
rhythms (p<0.001).  
Overall, the adjusted odds of ROSC at any time increased significantly with the use of 
adrenaline compared to placebo (adjusted OR: 4.72, 95% CI: 4.17-5.35). The results for 
sustained ROSC were similar although the estimated effect of adrenaline was smaller 
(adjusted OR: 3.82, 95% CI: 3.30-4.42) than for ROSC at any time.  
Survival (figure 2) 
For non-shockable rhythms, survival to discharge was 32/3020 (1.06%) in the adrenaline 
group and 13/3023 (0.43%) in the placebo group (adjusted OR: 2.52, 95% CI: 1.32-4.83).  For 
shockable rhythms survival to discharge was 89/717 (12.41%) in the adrenaline group and 
74/705 (10.50%) in the placebo group (adjusted OR: 1.27, 95% CI: 0.90-1.78).  However, the 
interaction term in the model, does not provide convincing evidence of difference in 
treatment effect across categories of cardiac rhythm (p=0.065). 
Overall, survival at discharge was higher in the adrenaline group compared to placebo 
(adjusted OR: 1.49, 95% CI: 1.10-2.00).  Similar results were noted for survival to 30 days and 
survival to 3 months. 
 
Favourable neurological outcome (figure 2) 
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The proportions with favourable neurological outcomes at hospital discharge were similar in 
the adrenaline group compared to the placebo group for non-shockable, 16/3020 (0.53%) 
versus 9/3023 (0.30%) (adjusted OR 1.79, 95% CI: 0.79, 4.08) and for shockable, 67/715 
(9.37%) versus 62/704 (8.81%); adjusted OR 1.10, 95% CI: 0.75-1.61).  Of those patients with 
non-shockable rhythms 16 survived to hospital discharge with a poor neurological outcome 
in the adrenaline group and 4 in the placebo group.  For patients with shockable rhythms, 23 
survived to discharge with a poor neurological outcome in the adrenaline group compared to 
12 in the placebo group.   
 
 
There was insufficient evidence to suggest that favourable neurological outcome at discharge 
differed between the treatment arms (OR: 1.20, 95% CI: 0.85-1.70, p=0.288), and it was not 
found to differ according to rhythm type (p=0.295).  Similar results were found for favourable 
neurological outcome at 3 months, although the rates of loss to follow-up were higher than 
at discharge (figure 1).  Where information was available at three months, for non-shockable 
rhythms 7 patients survived with poor neurological outcome in the adrenaline group and 6 in 
the placebo group.  For shockable rhythms, 9 patients were alive with poor neurological 
outcome in the adrenaline group and 5 in the placebo group. 
 
Sensitivity analyses 
The results for the un-adjusted analyses were similar to the adjusted analyses (see figure 3). 
 
Meta-analysis  
Meta-analyses of results from the two studies6,7  showed that the pooled odds of ROSC at any 
time in the shockable group was significantly higher for those given adrenaline (adjusted OR: 
2.30, 95%CI: 1.88-2.82) and the pooled effect in the non-shockable group was also greater 
with adrenaline (adjusted OR: 6.16, 95%CI: 5.30-7.15). The results for ROSC at any time were 
similar for both studies (I2=0.0%). Figure 4 illustrates these results. 
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The results for survival at discharge did not appear to differ substantially between studies 
(I2=0.0%). The pooled odds of survival at discharge for those with non-shockable rhythms 
increased with the use of adrenaline (adjusted OR: 2.57, 95%CI: 1.36-4.83), however, for 
patients with shockable rhythms the increase was smaller and more uncertain (adjusted OR: 
1.26, 95%CI: 0.93-1.71).  
Pooled odds of favourable neurological outcome at discharge suggested insufficient evidence 
of better neurological outcome with adrenaline compared to placebo in those with shockable 
rhythms (adjusted OR: 1.09, 95%CI: 0.77-1.53) and non-shockable rhythms (adjusted OR: 
1.91, 95%CI: 0.87-4.22). 
 
Discussion 
This paper reports that, relative to placebo, the effects of adrenaline on any ROSC and 
sustained ROSC appear to be greater for patients with an initially non-shockable arrest rhythm 
than those with shockable rhythms.  Similar patterns are observed for longer term survival 
outcomes and favourable neurological outcomes, although the differences in effect are less 
pronounced.  
 
The findings of the present study are consistent with previous research.  Olasveengen et al 
examined the effect of intravenous (IV) cannulation and injection of drugs versus not giving 
IV drugs in 851 adults with OHCA.18  The majority in the intervention group (79%) received 
adrenaline.  The trial found similar outcomes in the intervention and control arms for patients 
with an initially shockable rhythm (VF or pulseless VT).  By contrast, in patients in the 
intervention arm with initially non-shockable rhythms, a higher rate of ROSC (29% versus 
11%), admission to hospital (31% versus 16%) was observed although long term survival (3% 
versus 2%) and favourable neurological outcomes (2% in both groups) were similar.  The same 
pattern of outcomes was observed in a post hoc analysis of that trial which limited the analysis 
to patients who actually received adrenaline.19  In two large observational studies drawn from 
the Japanese Utstein-style registry for OHCA, researchers found no difference or worse 
outcomes in patients treated with adrenaline who had an initially shockable rhythm, whilst 
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those with non-shockable rhythms had better outcomes.8,10  During in-hospital cardiac arrest, 
drugs can be given much earlier than is possible in most cases of OHCA.  In this setting, in an 
analysis of the Get with the Guidelines Resuscitation Registry, Andersen et al showed that 
very early adrenaline administration (within the first two minutes of cardiac arrest)  was 
associated with worse outcomes in patients with shockable rhythms.9  Using the same 
registry, Donnino et al  reported that outcomes were better in non-shockable rhythms the 
earlier that adrenaline was administered.20  These reports, together with the findings from 
the present study, support the hypothesis that the relative effect of adrenaline in cardiac 
arrest is greater in non-shockable rhythms.  
 
The observed differences in treatment effect for adrenaline could be explained by differences 
in pathophysiology of cardiac arrest associated with shockable and non-shockable rhythms.  
A cardiac cause is more likely in patients who present with initially shockable rhythms.21  In 
these patients rapid treatment with defibrillation is the most effective intervention.22  
Although the present study did not find evidence adrenaline was harmful in patients with 
shockable rhythms, the β-adrenergic effects of adrenaline are potentially harmful and 
associated with increased myocardial oxygen demand,23 higher rates of re-arrest24 and worse 
myocardial dysfunction after return of spontaneous circulation.25 By contrast, there are few 
effective treatments for patients with non-shockable rhythms.  Some of the causes of cardiac 
arrest associated with non-shockable rhythms such impaired myocardial contractility, 
reduced systemic vascular resistance and failure of myocardial conduction may be more 
responsive to treatment with adrenaline.26,27  
 
This study has several limitations.  Although defined as an a priori analyses, exploration of the 
treatment effects of adrenaline according to the initial rhythm were not the primary intent of 
either the PACA or PARAMEDIC-2 study.  As such, the findings should be considered 
exploratory and interpreted with caution.  Both of the index trials (PACA and PARAMEDIC-2) 
recruited patients with OHCA.  The findings do not necessarily apply to in-hospital cardiac 
arrest, where the causes of cardiac arrest, time to treatment and accessibility to alternative 
treatments differ.  The analyses were based on the initial presenting arrest rhythm at time of 
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first assessment as opposed to the rhythm immediately before drug administration.  The trials 
examined intermittent boluses of adrenaline (1 mg) given every 3-5 minutes.  Alternative 
dosing strategies such as low dose, high dose, continuous infusions or titration according to 
invasive haemodynamic monitoring may yield different findings.  The trials occurred in 
settings where extracorporeal CPR was unavailable.  Patients with refractory cardiac arrest 
were therefore exposed to up to 10 doses of adrenaline before discontinuing resuscitation 
efforts.  The trials did not mandate a single, specific post resuscitation care protocol, instead 
treating clinicians were guided by current practice recommendations.28    Finally, the 
PARAMEDIC-2 findings for neurological outcome at 3 months are limited by overall small 
numbers and a higher rate of loss to follow-up than at discharge.  Since loss to follow-up is 
higher in those with poor neurological outcomes, the findings for outcomes after discharge 
are at risk of attrition bias.29,30  
 
This study highlights the need for further research around the on-going use of adrenaline in 
cardiac arrest when the initial rhythm is shockable.  Whilst this and other studies9 suggests 
that adrenaline may be less effective in shockable rhythms, particularly shortly after the onset 
of cardiac arrest, it is likely a transition point arises after which vasopressor therapy may be 
required to achieve ROSC.  This is consistent with the 3-phase model concept of electrical, 
circulatory and metabolic phases reflecting the time sensitive progression of resuscitation 
pathophysiology.22   Further research is required to identify when and if it is appropriate to 
transition from a primary focus on CPR and defibrillation to one which includes vasopressors 
and/or other therapies (e.g. extra-corporeal CPR).31,32  
 
In conclusion, the effects of adrenaline on any ROSC and sustained ROSC  are relatively greater 
for OHCA patients with an initially non-shockable rhythm than those with shockable rhythms.  
The patterns for longer term survival outcomes and favourable neurological outcomes, 
suggest similar effects, although the differences are less pronounced.  
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Missing rhythm type (n=96) Missing rhythm type (n=70) 
Allocated to Placebo 
  Received allocated intervention (n=3,999)   
Allocated to Adrenaline 
  Received allocated intervention (n=4,015) 
Lost to follow-up: 
  LTFU of survival at 30 days (n=0) 
  LTFU of survival at discharge (n=0) 
  LTFU of survival at 3 months (n=0) 
  LTFU of ROSC at admission (n=20) 
  LTFU of ROSC at any time (n=20) 
  LTFU of survival with favourable 
neurological outcome at discharge 
(n=0) 
  LTFU of survival with favourable 
neurological outcome at 3 months 
(n=8) 
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Analysed: 
Survival at 30 days (n=745) 
Survival at discharge (n=744) 
Survival at 3 months (n=742) 
ROSC at admission (n=742) 
ROSC at any time (n=739) 
Favourable neurological outcome at 
discharge (n=743) 
Favourable neurological outcome at 3 
months (n=732) 
Analysed:  
Survival at 30 days (n=767) 
Survival at discharge (n=764) 
Survival at 3 months (n=764) 
ROSC at admission (n=750) 
ROSC at any time (n=757) 
Favourable neurological outcome at 
discharge (n=762) 
Favourable neurological outcome at 3 
months (n=750) 
A
n
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Non-shockable rhythm (n=3,181) Non-shockable rhythm (n=3,149) 
Lost to follow-up: 
  LTFU of survival at 30 days (n=1) 
  LTFU of survival at discharge (n=0) 
  LTFU of survival at 3 months (n=2) 
  LTFU of ROSC at admission (n=8) 
  LTFU of ROSC at any time (n=20) 
  LTFU of survival with favourable 
neurological outcome at discharge 
(n=0) 
  LTFU of survival with favourable 
neurological outcome at 3 months 
(n=4) 
 
Lost to follow-up: 
  LTFU of survival at 30 days (n=3)
  LTFU of survival at discharge (n=6) 
  LTFU of survival at 3 months (n=6) 
  LTFU of ROSC at admission (n=20) 
  LTFU of ROSC at any time (n=13)
  LTFU of survival with favourable 
neurological outcome at discha ge 
(n=8) 
  LTFU of survival with favourable 
neurological outcome at 3 months 
(n=20) 
 
Lost to follow-up: 
  LTFU of survival at 30 days (n=3) 
  LTFU of survival at discharge (n=4) 
  LTFU of survival at 3 months (n=6) 
  LTFU of ROSC at admission (n=6) 
  LTFU of ROSC at any time (n=9) 
  LTFU of survival with favourable 
neurological outcome at discharge 
(n=5) 
  LTFU of survival with favourable 
neurological outcome at 3 months 
(n=16) 
 
Shockable rhythm (n=770) Shockable rhythm (n=748) 
Analysed: 
Survival at 30 days (n=3,180) 
Survival at discharge (n=3,181) 
Survival at 3 months (n=3,179) 
ROSC at admission (n=3,173) 
ROSC at any time (n=3,161) 
Favourable neurological outcome at 
discharge (n=3,181) 
Favourable neurological outcome at 3 
months (n=3,177) 
Analysed:  
Survival at 30 days (n=3,149) 
Survival at discharge (n=3,149) 
Survival at 3 months (n=3,149) 
ROSC at admission (n=3,129) 
ROSC at any time (n=3,129) 
Favour ble neurological outcome at 
discharge (n=3,149) 
Favour ble neurological outcome at 3 
months (n=3,141) 
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Note: LTFU are counted separately and are not cumulative 
 
Figure 1: CONSORT diagram of allocation and outcomes by rhythm type 
 
 
Figure 2: Adjusted odds ratio (95% CI, p) of adrenaline vs placebo on primary and secondary outcomes (by initial cardiac rhythm) 
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Note: Models adjusted for age, gender, interval between emergency call and ambulance arrival at scene, interval between ambulance arrival and drug administration, aetiology, witness type, 
bystander CPR, and initial rhythm 
 
 
 
 
 
 
Figure 3: Unadjusted odds ratio (95% CI, p) of adrenaline vs placebo on primary and secondary outcomes (by initial cardiac rhythm)  
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Figure 4: Random effects meta-analyses with pooled odds ratio (95% CI, I2) of adrenaline vs placebo on ROSC at any time and survival at discharge (by initial cardiac rhythm) 
 
Note: * Effect size not estimable 
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Table 1: Patient characteristics by initial rhythm (shockable and non-shockable) (n=7848) 
 Shockable 
(n=1518) 
Non-shockable 
(n=6330) 
Overall 
(n=7848) 
Test 
statisticǂ 
p-value 
Age (years)*      
Mean (SD) 67.30 (14.59) 70.36 (16.80) 69.77 (16.44) -6.53 <0.001 
Median (IQR) 69.01 (21.64) 73.73 (22.98) 72.67 (22.90)   
      
Gender      
Female 322 (21.21%) 2444 (38.61%) 2766 (35.24%) 162.38 <0.001 
Male 1196 (78.79%) 3886 (61.39%) 5082 (64.76%)   
      
Time from 999 call to treatment 
(minutes) 
     
<10 78 (5.14%) 406 (6.41%) 484 (6.17%)   
10-20 620 (40.84%) 2288 (36.15%) 2908 (37.05%)   
>20 799 (52.64%) 3586 (56.65%) 4385 (55.87%)   
Unknown 21 (1.38%) 50 (0.79%) 71 (0.90%)   
Mean (SD) 21.87 (9.28) 22.90 (11.53) 22.70 (11.14) -3.22 0.001 
Median (IQR) 20.55 (10.50) 21.57 (11.53) 21.37 (11.28)   
      
Initial aetiology      
Medical (presumed cardiac) 1474 (97.10%) 5760 (91.00%) 7234 (92.18%) 63.30 <0.001 
Traumatic cause 8 (0.53%) 108 (1.71%) 116 (1.48%)   
Drowning 1 (0.07%) 19 (0.30%) 20 (0.25%)   
Drug overdose 4 (0.26%) 139 (2.20%) 143 (1.82%)   
Electrocution 0 (0.00%) 1 (0.02%) 1 (0.01%)   
Asphyxia 2 (0.13%) 186 (2.94%) 188 (2.40%)   
Unknown 29 (1.91%) 117 (1.85%) 146 (1.86%)   
      
Witnessed by      
Unwitnessed 280 (18.45%) 2677 (42.29%) 2957 (37.68%) 296.48 <0.001 
EMS witnessed 135 (8.89%) 763 (12.05%) 898 (11.44%)   
Bystander witnessed 1080 (71.15%) 2838 (44.83%) 3918 (49.92%)   
Unknown 23 (1.52%) 52 (0.82%) 75 (0.96%)   
      
Bystander commenced CPR      
Yes 1042 (68.64%) 3607 (56.98%) 4649 (59.24%) 571.30 <0.001 
NoϮ 443 (29.18%) 2631 (41.56%) 3074 (39.17%)   
Unknown 33 (2.17%) 92 (1.45%) 125 (1.59%)   
      
Patient transported to hospital      
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Yes 1025 (67.52%) 2159 (34.11%) 3184 (40.57%) 567.03 <0.001 
No 493 (32.48%) 4171 (65.89%) 4664 (59.43%)   
      
Declared deceased by ED staff      
Yes 445 (29.31%) 1195 (18.88%) 1640 (20.90%) 80.68 <0.001 
No 350 (23.06%) 528 (8.34%) 878 (11.18%)   
Not applicable/not transported 493 (32.48%) 4171 (65.89%) 4664 (59.43%)   
Unknown 230 (15.15%) 436 (6.89%) 666 (8.49%)   
      
Note: an additional n=166 patients had no rhythm recorded. * n=2 shockable and n=7 non-shockable patients had no recorded age. Ϯ includes EMS witnessed cases. ǂ Produced using the t-test for continuous variables 
and the chi-squared test for categorical variables. 
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